Combinatorial PNA-CPP Molecules Targeting Plasmid Transfer and Replication to Control Antibiotic Resistance

Award Information
Agency:
Department of Defense
Branch
Defense Advanced Research Projects Agency
Amount:
$99,999.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
W31P4Q-13-C-0025
Agency Tracking Number:
D122-001-0161
Solicitation Year:
2012
Solicitation Topic Code:
SB122-001
Solicitation Number:
2012.2
Small Business Information
Agave BioSystems, Inc.
P.O. Box 100, Ithaca, NY, -
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
N
Duns:
022552900
Principal Investigator:
Zoey Ni
Staff Scientist
(607) 272-0002
zni@agavebio.com
Business Contact:
Noe Salazar
President
(607) 272-0002
nsalazar@agavebio.com
Research Institution:
Stub




Abstract
One major cause of the widespread of drug-resistant and virulent bacteria pathogen is the horizontal gene transfer of resistance and virulence genes in the form of plasmids. As proof-of concept for this Phase I effort, Agave BioSystems proposes to develop combinatorial therapeutics by inhibiting conserved genes involved in multiple steps of plasmid transfer and replication using peptide nucleic acid (PNA) antisense oligonucleotides and cell penetrating peptides (CPPs) in both gram-negative bacteria Escherichia coli and gram-positive strain Enterococcus faecalis. These PNA-CPPs are designed to suppress the expression of the critical enzymes involved in the plasmid transfer and replication in the pathogenic microorganisms. The proposed system has the potential to inhibit the spread of drug resistance genes to susceptible strains and eventually eliminate the drug resistance of the host microbes.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government